| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/07/2023 | 53.3% | HC Wainwright & Co. | $14 → $15 | Maintains | Buy |
| 07/06/2023 | 53.3% | Cantor Fitzgerald | → $15 | Reiterates | Overweight → Overweight |
| 05/03/2023 | 43.08% | HC Wainwright & Co. | → $14 | Reiterates | → Buy |
| 02/23/2023 | 12.42% | RBC Capital | → $11 | Reiterates | → Outperform |
| 01/04/2023 | 12.42% | RBC Capital | $10 → $11 | Maintains | Outperform |
| 11/07/2022 | 43.08% | HC Wainwright & Co. | $26 → $14 | Maintains | Buy |
| 11/04/2022 | 2.2% | RBC Capital | $18 → $10 | Maintains | Outperform |
| 11/04/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 11/04/2022 | 22.64% | SVB Leerink | $17 → $12 | Maintains | Outperform |
| 08/09/2022 | 165.71% | HC Wainwright & Co. | $30 → $26 | Maintains | Buy |
| 08/08/2022 | 32.86% | Oppenheimer | $15 → $13 | Maintains | Outperform |
| 05/05/2022 | 155.49% | Cantor Fitzgerald | → $25 | Assumes | → Overweight |
| 05/05/2022 | 206.59% | HC Wainwright & Co. | $33 → $30 | Maintains | Buy |
| 04/28/2022 | 124.83% | RBC Capital | $27 → $22 | Maintains | Outperform |
| 03/08/2022 | 124.83% | SVB Leerink | $30 → $22 | Maintains | Outperform |
| 03/01/2022 | 175.93% | RBC Capital | $31 → $27 | Maintains | Outperform |
| 02/23/2022 | 216.81% | RBC Capital | $34 → $31 | Maintains | Outperform |
| 12/10/2021 | 216.81% | Oppenheimer | $33 → $31 | Upgrades | Perform → Outperform |
| 11/04/2021 | 237.25% | Oppenheimer | $32 → $33 | Maintains | Perform |
| 11/04/2021 | 308.79% | HC Wainwright & Co. | $35 → $40 | Maintains | Buy |
| 11/04/2021 | 257.69% | SVB Leerink | $28 → $35 | Maintains | Outperform |
| 10/28/2021 | 227.03% | Oppenheimer | $28 → $32 | Downgrades | Outperform → Perform |
| 10/26/2021 | 247.47% | RBC Capital | $23 → $34 | Maintains | Outperform |
| 01/27/2021 | 186.15% | SVB Leerink | $24 → $28 | Maintains | Outperform |
| 01/25/2021 | 257.69% | HC Wainwright & Co. | $30 → $35 | Maintains | Buy |
| 11/03/2020 | 186.15% | HC Wainwright & Co. | $34 → $28 | Maintains | Buy |
| 08/12/2020 | 247.47% | HC Wainwright & Co. | $33 → $34 | Maintains | Buy |
| 07/22/2020 | 237.25% | HC Wainwright & Co. | $32 → $33 | Maintains | Buy |
| 03/06/2020 | 227.03% | Cantor Fitzgerald | $30 → $32 | Maintains | Overweight |
| 12/16/2019 | 227.03% | HC Wainwright & Co. | $25 → $32 | Maintains | Buy |
| 09/10/2019 | 43.08% | Oppenheimer | → $14 | Initiates Coverage On | → Outperform |
| 03/20/2019 | 12.42% | Raymond James | $9 → $11 | Maintains | Outperform |
What is the target price for Aurinia Pharmaceuticals (AUPH)?
The latest price target for Aurinia Pharmaceuticals (NASDAQ: AUPH) was reported by HC Wainwright & Co. on August 7, 2023. The analyst firm set a price target for $15.00 expecting AUPH to rise to within 12 months (a possible 53.30% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Aurinia Pharmaceuticals (AUPH)?
The latest analyst rating for Aurinia Pharmaceuticals (NASDAQ: AUPH) was provided by HC Wainwright & Co., and Aurinia Pharmaceuticals maintained their buy rating.
When is the next analyst rating going to be posted or updated for Aurinia Pharmaceuticals (AUPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aurinia Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aurinia Pharmaceuticals was filed on August 7, 2023 so you should expect the next rating to be made available sometime around August 7, 2024.
Is the Analyst Rating Aurinia Pharmaceuticals (AUPH) correct?
While ratings are subjective and will change, the latest Aurinia Pharmaceuticals (AUPH) rating was a maintained with a price target of $14.00 to $15.00. The current price Aurinia Pharmaceuticals (AUPH) is trading at is $9.79, which is out of the analyst's predicted range.